Results 221 to 230 of about 2,636,203 (317)

Letter to the Editor: "Reducing the Risk of Developing Diabetes: The Role of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in Patients With Hypertension Combined Prediabetes". [PDF]

J Clin Hypertens (Greenwich)
Ayesha S, Ishtiaq S, Ali MI, Huda NU.
europepmc   +1 more source

Epoxide hydrolase (EPHX2); angiotensin II type 1 receptor (AGTR1) [PDF]

, 2009
Bruce D. Hammock
openalex   +1 more source

Significance of angiotensin 1–7 coupling with MAS1 receptor and other GPCRs to the renin‐angiotensin system: IUPHAR Review 22

British Journal of Pharmacology, 2017
S. Karnik, K. D. Singh, Kalyan C. Tirupula, Hamiyet Unal   +3 more
semanticscholar   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

A Letter to the Editor on "Reducing the Risk of Developing Diabetes: The Role of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in Patients with Hypertension Combined Prediabetes". [PDF]

J Clin Hypertens (Greenwich)
Khan G.
europepmc   +1 more source

Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis [PDF]

, 2013
Li Song, Suli Zhang, Kehua Bai, Jie Yang, Haiyan Xiong, Xiao Li, Teng Liu, Huirong Liu   +7 more
openalex   +1 more source

Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography

Cell, 2015
Haitao Zhang, Hamiyet Unal, C. Gati, G. Han, Wei Liu, N. Zatsepin, Daniel James, Dingjie Wang, G. Nelson, U. Weierstall, M. Sawaya, Qingping Xu, M. Messerschmidt, Garth J. Williams, S. Boutet, O. Yefanov, T. White, Chong Wang, A. Ishchenko, Kalyan C. Tirupula, R. Desnoyer, J. Coe, C. Conrad, P. Fromme, R. Stevens, V. Katritch, S. Karnik, V. Cherezov   +27 more
semanticscholar   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Withholding vs. continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before surgery: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med
Dou W, Hu JH, Long YQ, Liu H, Ji FH, Sudhan N, Peng K.   +6 more
europepmc   +1 more source

Neuroprotective effects of angiotensin receptor blockers.

American Journal of Hypertension, 2015
S. Villapol, J. Saavedra
semanticscholar   +1 more source